NKTR, Nektar Therapeutics and NASDAQ

Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Oppenheimer
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued on Friday,
Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 EPS, expectations were $-0.13. Operator: Good day, and thank you for standing by.
Oppenheimer Upgrades Nektar Therapeutics (NKTR)
Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from Perform to Outperform. Analyst Price Forecast Suggests 418.64% Upside As of March 3,
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a strong cash position.
Nektar Therapeutics (NASDAQ:NKTR) Earns Market Perform Rating from William Blair
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William Blair in a research note issued to investors on Thursday,RTT News reports. Several other research analysts also recently commented on the company.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Nektar (NKTR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Nektar Therapeutics (NKTR) Gets a Buy from Piper Sandler
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...
Nektar upgraded to Outperform at Oppenheimer ahead of rezpeg readout in June
Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...
Nasdaq3d
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
Nektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 13 cents. In the year-ago quarter ...